Stoke Therapeutics reports a Schedule 13G/A showing beneficial ownership of 4,763,673 shares (8.1% of the class). The filing states this percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026. The holdings are reported by Lynx1 Capital Management LP and Weston Nichols and consist of 4,121,244 shares previously reported for the quarter ended March 31, 2026 plus an additional 642,429 shares.
Positive
None.
Negative
None.
Insights
Large holder disclosure: Lynx1 reports an 8.1% stake via 4,763,673 shares.
Lynx1 Capital Management LP and Mr. Weston Nichols jointly report 4,763,673 shares of Common Stock, representing 8.1% of the class based on 59,150,790 shares outstanding as of February 28, 2026. The filing combines previously reported holdings of 4,121,244 shares with an additional 642,429 shares as of March 31, 2026.
The disclosure is a standard beneficial-ownership update under Schedule 13G/A and does not state how or when any shares may be sold; cash-flow treatment and disposition intentions are not disclosed in the excerpt.
Filing attributes shared voting and dispositive power to the reporting persons.
The cover-page rows show shared voting power and shared dispositive power of 4,763,673 shares for the Reporting Persons. The Lynx1 Fund is identified as having the right to receive dividends or sale proceeds for these shares.
The statement contains standard cautionary language about Section 13 beneficial ownership and cites the Company’s Form 10-K for the outstanding share count; subsequent filings may further detail ownership changes.
Key Figures
Shares beneficially owned:4,763,673 sharesPercent of class:8.1%Shares outstanding:59,150,790 shares+2 more
5 metrics
Shares beneficially owned4,763,673 sharesBeneficial ownership reported by Lynx1 and Weston Nichols
Percent of class8.1%Calculated using 59,150,790 shares outstanding as of Feb 28, 2026
Shares outstanding59,150,790 sharesAs of <date>February 28, 2026</date> per the company Form 10-K
Previously reported shares4,121,244 sharesReported for quarter ended <date>March 31, 2026</date>
Additional shares642,429 sharesAdditional beneficially owned shares as of <date>March 31, 2026</date>
Key Terms
Schedule 13G/A, Beneficial ownership, Shared Dispositive Power, Sole Voting Power
4 terms
Schedule 13G/Aregulatory
"This statement is filed by: Lynx1 Capital Management LP... (Schedule 13G/A context)"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownershipregulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 4,763,673.00"
Sole Voting Powerregulatory
"Sole Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Lynx1 reports beneficial ownership of 4,763,673 shares, representing 8.1% of the class. This percentage is calculated using 59,150,790 shares outstanding as of February 28, 2026 per the company’s Form 10-K.
Who are the reporting persons in this Schedule 13G/A for STOK?
The filing is made by Lynx1 Capital Management LP (the Investment Manager) and Weston Nichols, the sole member of the general partner, reporting holdings held by the Lynx1 Fund and a managed account.
How is the reported 4,763,673 share total constructed?
The filing states the total includes 4,121,244 shares previously reported for the quarter ended March 31, 2026 plus an additional 642,429 shares beneficially owned on that date, totaling 4,763,673 shares.
Does the Schedule 13G/A state voting or dispositive power?
Yes; the cover-page rows report shared voting power and shared dispositive power of 4,763,673 shares for the Reporting Persons. Sole voting and dispositive powers are reported as 0.00 on the cover page.
Who receives proceeds or dividends for the reported shares?
The filing states that the Lynx1 Fund has the right to receive dividends or proceeds from the sale of the shares reported in this Schedule 13G/A; no other payee is identified in the excerpt.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Stoke Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
86150R107
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Lynx1 Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,763,673.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,763,673.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,763,673.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.1 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Weston Nichols
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,763,673.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,763,673.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,763,673.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Stoke Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
45 Wiggins Ave, Bedford, Massachusetts 01730.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund") and a managed account, with respect to the common stock par value $0.0001 per share ("Common Stock"), of Stoke Therapeutics, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund and the managed account; and
(ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the Common Stock directly held by the Lynx1 Fund and the managed account.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
Weston Nichols
c/o Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
(c)
Citizenship:
Investment Manager - Delaware
Mr. Nichols - United States of America
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
86150R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 59,150,790 shares of Common Stock outstanding as of February 28, 2026, as reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 16, 2026.
The amount of Common Stock set forth in rows (6), (8), and (9) of the cover page of each of the Reporting Persons includes 4,121,244 shares of Common Stock previously reported on Schedule 13G for the quarterly period ending March 31, 2026, filed with the Securities Exchange Commission on May 15, 2026, plus an additional 642,429 shares of Common Stock also beneficially owned by the Reporting Persons on March 31, 2026.
(b)
Percent of class:
8.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Lynx1 Capital Management LP
Signature:
/s/ Weston Nichols
Name/Title:
By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
